Pacylex Pharmaceuticals

Pacylex Pharmaceuticals PCLX-001 kills leukemia and lymphoma tumors in animals. Clinical studies in 2020.

Pacylex is a Canadian oncology company exploiting a new target in cancer biology with a first-in-class, oral drug to kill cancer cells while leaving normal cells unharmed.

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).
11/04/2025

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the W...
11/04/2025

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the World ADC Congress in San Diego. ADCs with zelenirstat were 20->1,000 fold more potent against prostate and breast cancer cell lines than zelenirstat alone including a breast cancer line resistant to most ADCs.
https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-and-heidelberg-pharma-present-zelenirstat-antibody-drug-conjugate-data-at-the-16th-annual-world-adc?_gl=1*1hxfm9e*_gcl_au*MzAwNzk1NDg0LjE3NTU0NTcyMzQuMTcyNDM5NjU5Ni4xNzYyMjI4MjYyLjE3NjIyMjgyNzQ.

Edmonton, Alberta, Canada and Heidelberg Pharma, Ladenburg, Germany, November 4, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Heidelberg Pharma AG (FSE: HPHA) is a clinical...

Address

4000, 10230 Jasper Avenue
Edmonton, AB
T5J4P6

Website

Alerts

Be the first to know and let us send you an email when Pacylex Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Pacylex Pharmaceuticals:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Building a NEW Cancer Therapy

Pacylex is a Canadian oncology company exploiting a new discovery in cancer biology which may explain how some cancers arise from normal cells. The company is developing a first in class, small molecule, oral chemotherapeutic, PCLX-001, to exploit this cancer mechanism by turning on selective lethality, apoptosis, in these cancer cells. Animal tests show this drug candidate completely eliminates tumors in 4 different animal models of blood cancers (leukemias and lymphomas). PCLX-001 also kills many solid tumor cancer cell lines and retards tumor growth in some animal models of lung and breast cancer.

Long-term survival of patients with lymphoma and especially leukemia is poor. The lymphoma market is ~$5B with few new therapies. The leukemia market is transitioning from generic chemotherapy to new branded therapies and is expected to grow dramatically in the next decade to >$1.9B. Oncology is the area of greatest pharmaceutical company interest and this summer, Pacylex was accepted into the first class of 4 companies in the new Merck-sponsored Accelerator in Edmonton, and is pursuing the investment and experiments necessary to begin investigations in patients.